A cystic fibrosis carrier test looks for disease-associated variants in CFTR, the gene that controls chloride and bicarbonate transport across epithelial cells. Most people with one CF-causing variant are healthy carriers. The key reproductive question is whether the other biological parent also carries a CFTR variant that can cause cystic fibrosis when paired with the first. If both partners carry CF-causing variants, each pregnancy usually has a 25% chance of cystic fibrosis. Test design strongly affects the result. Older panels often assessed 23 common variants, while the American College of Medical Genetics and Genomics expanded its recommended minimum carrier-screening set to 100 variants in 2023. Some laboratories sequence much more of CFTR and assess deletions, duplications, and the intron 8 poly-T/TG region. A negative result lowers risk but never removes it completely. A positive result must be interpreted by variant class, phase, partner findings, family history, and whether the testing is for carrier screening or diagnosis.
- A carrier result usually means one CF-causing CFTR variant was found.
- Panel size, sequencing coverage, copy-number analysis, and ancestry influence detection rate.
- Partner testing should use an appropriate method capable of detecting a different CFTR variant.
- Two CF-causing variants in trans support cystic fibrosis; some combinations cause a CFTR-related disorder instead.
- Variants of varying clinical consequence and poly-T/TG alleles require more nuanced interpretation.
- Sweat chloride testing remains central when an infant, child, or adult is being evaluated for disease.
Table of Contents
- What CFTR Carrier Screening Answers
- Who Is Offered Testing
- Choosing a Panel or Sequencing Test
- Variant Classes and Special Alleles
- Understanding Your Report
- Partner Risk and Residual Risk
- Carrier Screening Versus CF Diagnosis
- Pregnancy, Family, and Follow-Up Decisions
What CFTR Carrier Screening Answers
CFTR encodes the cystic fibrosis transmembrane conductance regulator, an ion channel found in the lungs, pancreas, intestines, sweat glands, reproductive tract, and other tissues. When both gene copies have sufficiently disruptive variants, salt and water movement is altered. Thick secretions, chronic airway disease, pancreatic insufficiency, elevated sweat chloride, male infertility from congenital absence of the vas deferens, and other manifestations can result.
Carrier screening asks whether an apparently unaffected person has one clinically important CFTR variant that could be passed to a child. It is not a complete health assessment and does not directly test lung function, pancreatic function, fertility, or sweat chloride. One positive variant usually establishes carrier status but not cystic fibrosis.
CFTR-related phenotypes form a spectrum. At one end is classic cystic fibrosis involving multiple organs. At the other are single-organ conditions such as CFTR-related congenital bilateral absence of the vas deferens, recurrent pancreatitis, or bronchiectasis. Between them are inconclusive newborn-screening categories and milder disease. The clinical outcome depends on the two-variant combination, how much CFTR function remains, and other modifiers.
More than two thousand CFTR variants have been described, but not all cause disease. Some clearly disrupt CFTR, some have variable consequences, some are benign, and many remain uncertain. Carrier screening therefore should not count every DNA difference as a positive result.
A confirmed carrier generally has a 50% chance of passing the variant in each pregnancy. If the other parent does not carry a clinically relevant CFTR variant, children may be carriers but are not expected to have autosomal recessive CF from that pairing. If both partners carry CF-causing variants, the familiar 25% affected risk applies.
Carriers usually do not need cystic fibrosis treatment. Research suggests that some heterozygotes may have small increases in selected CFTR-related health risks, but most remain healthy, and a carrier result alone does not diagnose a CFTR-related disorder. Symptoms should be evaluated on their own merits.
Who Is Offered Testing
CF carrier screening is commonly offered to people planning pregnancy and those already pregnant. It may also be part of donor egg or sperm evaluation, fertility treatment, or an expanded carrier panel. Current practice favors broad access rather than limiting screening to people of Northern European ancestry because CFTR variants occur in every population and detection gaps have historically been larger in underrepresented groups.
Testing is particularly important when:
- A reproductive partner is a confirmed CFTR carrier.
- A close relative has cystic fibrosis or a CFTR-related disorder.
- A previous child or pregnancy was affected.
- A person has a family-specific CFTR variant.
- A sperm donor or egg donor report includes a CFTR finding.
- Infertility evaluation shows congenital bilateral absence of the vas deferens.
- Newborn screening or sweat testing creates a diagnostic question.
For a known family history, obtain the affected relative’s molecular report. The family may carry a rare variant absent from a routine panel. Targeted testing for that exact change can be added to, or substituted for, standard carrier screening depending on the situation.
Preconception testing offers the most time. If one partner is positive, the other can be tested, results can be clarified, and reproductive options can be discussed before pregnancy. During pregnancy, concurrent testing of both partners may be practical when sequential testing would create delay.
A previous negative test should be reviewed rather than automatically repeated. Ask how many variants were tested, whether the result predates the 2023 ACMG update, whether full sequencing or copy-number analysis was performed, and whether the family’s variant was included. Technology and recommended minimum content have changed.
Children are generally not tested solely to learn future carrier status when no current medical benefit exists. Diagnostic testing is different. A child with symptoms, a positive newborn screen, or a sibling with CF may need CFTR analysis and sweat chloride testing because the result affects current care.
The decision to screen remains voluntary. Pretest counseling should cover possible findings beyond a simple positive or negative result, including variants of varying clinical consequence, uncertain findings, and alleles associated mainly with male infertility or milder disease.
Choosing a Panel or Sequencing Test
CFTR carrier tests range from targeted genotyping to comprehensive gene analysis. The name “CF screen” does not reveal which was used.
A targeted panel examines a fixed set of variants. For many years, the common U.S. minimum was the ACMG-23 panel. In 2023, ACMG recommended a new minimum set of 100 variants for pan-ethnic carrier screening. The expansion improves detection across a more diverse population, but 100 remains a minimum, not a complete list of every CF-causing variant.
Full CFTR sequencing analyzes the coding exons and nearby splice regions for many substitutions and small insertions or deletions. Some laboratories include selected deep intronic or regulatory variants. Deletion and duplication analysis detects larger missing or extra segments that sequence analysis may miss.
The intron 8 poly-T tract, often described as 5T, 7T, or 9T, and the adjacent TG repeat can modify splicing. Laboratories vary in when they analyze and report it. It is especially relevant when p.Arg117His, commonly written R117H, is detected or when congenital absence of the vas deferens is under evaluation.
A practical comparison is:
| Test design | Strength | Main limitation |
|---|---|---|
| Small founder/common-variant panel | Fast and inexpensive | Lower detection outside represented variants |
| ACMG minimum 100-variant panel | Broader standardized carrier detection | Still misses rare CFTR variants |
| Full sequencing | Detects many rare sequence variants | May report more complex or uncertain findings |
| Sequencing plus deletion/duplication analysis | Most comprehensive routine carrier approach | Does not detect every deep intronic or regulatory change |
| Targeted familial testing | Accurate for a known family variant | Does not assess unrelated CFTR variants unless expanded |
For the reproductive partner of a known carrier, a broad method is usually preferable to testing only for the first partner’s exact variant. Unrelated partners commonly carry different variants. The laboratory should confirm that the first person’s variant is within its reportable range and that both results use compatible classification systems.
The specimen is usually blood, saliva, or a cheek swab. No fasting is required. Results may take several days to several weeks depending on scope and confirmation needs.
A large panel is not automatically better if variant interpretation is poor. Ask whether the laboratory uses expert resources such as CFTR2, follows current technical standards, confirms copy-number changes, and clearly labels CF-causing versus variable-consequence variants.
Variant Classes and Special Alleles
CFTR interpretation uses more clinical categories than many recessive carrier tests. A variant may be classified as CF-causing, non-CF-causing, of varying clinical consequence, or uncertain. The standard pathogenic/likely pathogenic/benign/VUS framework may also appear.
CF-causing variants have sufficient evidence that two such variants in trans can cause cystic fibrosis. F508del, written p.Phe508del, is the most common example in many populations. It removes one amino acid and disrupts CFTR processing.
Variants of varying clinical consequence can be associated with CF in some people and milder or no disease in others, depending on the second variant and modifiers. A reproductive report should not present them as identical to classic severe alleles without explanation.
CFTR-related-disorder variants may be linked more strongly to pancreatitis, bronchiectasis, or absence of the vas deferens than to classic childhood CF. Their importance depends on the paired allele.
Variants of uncertain significance lack enough evidence for clinical classification. Routine carrier screens often avoid reporting VUS findings because they are not suitable for defining an at-risk couple. Diagnostic sequencing is more likely to report them, especially when a person has symptoms.
R117H illustrates the need for haplotype context. Its effect is influenced by the poly-T tract on the same chromosome. R117H linked with 5T generally reduces normal splicing more than R117H linked with 7T. The number of adjacent TG repeats also modifies the effect of 5T. The laboratory may need parental or family testing to determine whether R117H and the poly-T/TG allele are in cis.
A 5T allele without R117H is common and has reduced penetrance. Certain TG repeat lengths increase the chance of abnormal splicing. Depending on the opposite CFTR variant, the combination may be associated with male infertility, a CFTR-related disorder, or occasionally a broader phenotype. It should not be translated into a simple “CF carrier” label without the full haplotype.
Complex alleles contain two or more variants on the same CFTR chromosome. Their combined effect can differ from either variant alone. Phase—whether variants are in cis or in trans—is essential when more than one finding appears in one person.
Variant classifications can change as functional and clinical data accumulate. The exact variant and report date should be retained for future review.
Understanding Your Report
A well-written report identifies the variant, zygosity, classification, test method, and limitations. The result can then be sorted into several common patterns.
One CF-causing variant detected. In an asymptomatic person, this usually means carrier status. Partner testing is the main reproductive follow-up. A carrier is not expected to have classic cystic fibrosis from one variant alone.
No reportable variant detected. The person’s carrier probability is reduced according to the test’s detection rate. It is not reduced to zero. A negative 23-variant panel leaves more residual risk than a negative comprehensive analysis, especially in populations where those variants have lower coverage.
Two CF-causing variants detected. The laboratory must determine whether they are in trans. In a person with symptoms or an abnormal newborn screen, two CF-causing variants in trans support a CF diagnosis, although sweat testing remains important. In an apparently healthy adult, the finding may represent mild variants, unrecognized disease, or variants in cis and needs specialist review.
One CF-causing variant plus a variable-consequence allele. The result cannot be summarized by the standard 25% severe-CF model without variant-specific counseling. The paired genotype may cause classic CF, a milder CFTR-related disorder, male infertility, or no disease.
VUS detected. A VUS does not establish carrier status for reproductive decisions and should not be used alone for prenatal diagnosis. Family segregation, functional testing, and updated databases may later clarify it. The general framework is explained in a genetic variant results guide.
Indeterminate or technically limited result. Low coverage, sample problems, possible mosaicism, or an unresolved copy-number change may require repeat or alternative testing.
Reports sometimes use legacy variant names. F508del may appear as ΔF508, and R117H may be written in several formats. A laboratory or genetic counselor can confirm equivalence. Do not assume two differently written names are different variants.
The report’s detection-rate table may be ancestry-specific. Self-identified ancestry can be incomplete, and estimates may not exist for every group. Comprehensive sequencing can reduce disparities but still cannot calculate zero risk.
Partner Risk and Residual Risk
When both partners carry CF-causing variants, each pregnancy generally has:
- A 25% chance of inheriting both variants and having cystic fibrosis.
- A 50% chance of inheriting one variant and being a carrier.
- A 25% chance of inheriting neither familial variant.
These probabilities reset with every conception. The expected severity depends on the specific pair. Two variants associated with minimal CFTR function often predict pancreatic insufficiency, while other combinations retain more function. Lung severity remains difficult to predict because modifiers and environment matter.
If one partner is a carrier and the other tests negative, the chance of an affected pregnancy is low but not zero. Residual risk starts with the negative partner’s pretest carrier probability and accounts for the proportion of carriers the assay would miss. The approximate affected-pregnancy risk is the residual carrier risk multiplied by one quarter.
A result from a limited panel should not be combined with the residual-risk estimate for a sequencing test. Use the tested person’s actual laboratory report. If the positive partner carries a rare variant, ask whether the negative partner’s assay included full sequencing and copy-number analysis.
If one partner carries a variable-consequence allele, risk counseling becomes genotype-specific. The couple may have a risk for classic CF, a CFTR-related disorder, or an uncertain phenotype. CFTR2 entries and an experienced genetics or CF center can help classify the exact combination.
Biological relatedness between partners can increase the chance of sharing a rare familial variant. A strong CF family history can also justify deeper testing after a negative routine screen. Testing an affected relative first remains the best way to identify the family’s variants.
A partner’s negative newborn screen from infancy is not a carrier test. Newborn screening is designed to find affected babies, not all heterozygous adults. Likewise, a normal sweat chloride result does not reliably exclude carrier status.
The broader principles of combining two reproductive results are covered in an autosomal recessive partner-risk guide. CFTR requires extra care because not every variant pair has the same clinical consequence.
Carrier Screening Versus CF Diagnosis
Carrier testing and diagnostic testing overlap in technology but answer different questions. Carrier screening is performed in a generally healthy person to assess reproductive risk. Diagnostic evaluation is performed because of symptoms, a positive newborn screen, family history, or another clinical concern.
The sweat chloride test remains the principal functional diagnostic test. It is performed at an experienced center using pilocarpine iontophoresis. A result of 60 mmol/L or higher supports CF in the appropriate context. Intermediate values require additional evaluation, and a low value does not exclude every CFTR-related disorder.
Newborn screening commonly begins with immunoreactive trypsinogen, or IRT, followed by one or more DNA tiers. Screening algorithms differ by region. A positive newborn screen is not a diagnosis and should lead to timely sweat testing. DNA panels can miss rare variants, especially in populations underrepresented in panel design.
A diagnosis can be supported by a compatible clinical presentation plus evidence of CFTR dysfunction, such as elevated sweat chloride or two CF-causing variants in trans. Nasal potential difference or intestinal current measurement may be used in specialized centers when sweat and genetics are inconclusive.
Some infants are labeled CFTR-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis—CRMS/CFSPID—when screening and testing do not meet full CF criteria. These children need structured follow-up because some later meet diagnostic criteria or develop CFTR-related symptoms, while many remain well.
Adults with recurrent pancreatitis, bronchiectasis, chronic sinus disease, or congenital absence of the vas deferens may have a CFTR-related disorder without classic CF. A carrier-screen result alone cannot settle that question. Comprehensive sequencing, poly-T/TG analysis, sweat chloride, and specialist evaluation may be needed.
For a person with confirmed CF, the exact genotype can affect eligibility for CFTR modulator therapy. This is a treatment issue distinct from carrier screening. A carrier should not take a modulator based solely on one variant.
Pregnancy, Family, and Follow-Up Decisions
When a carrier result is positive, obtain the full report, verify the classification, and arrange partner testing. Do not rely on a portal note that says only “CF positive.” The exact variant and method determine the next step.
When both partners are at risk, reproductive options include natural conception without fetal testing, prenatal diagnosis, IVF with PGT-M, donor eggs or sperm, donor embryos, adoption, and preparation for a child with CF. Values, disease expectations, access, and cost shape individual decisions.
Prenatal diagnosis can test DNA from chorionic villus sampling or amniocentesis for the known parental variants. PGT-M uses IVF and a customized embryo test. Both require clear variant classification and phase. Cell-free DNA screening is not a substitute for diagnostic CFTR testing.
A fetal genotype may not predict exact lung severity, treatment response, or life course. Current CF care and CFTR modulators have changed outcomes substantially, but eligibility and response depend on genotype, age, health system, and future approvals. Counseling should use current specialist information rather than outdated survival descriptions.
Adult relatives may choose targeted testing for the familial variant. Full siblings of a carrier often have a 50% chance of carrying it, depending on the parent’s status. The result may matter for their partners and pregnancies. Sharing the laboratory report prevents errors.
Common mistakes to avoid are:
- Treating a negative limited panel as zero risk.
- Testing the partner only for the first person’s exact variant.
- Assuming every pathogenic CFTR variant causes classic CF in every combination.
- Ignoring poly-T/TG context with R117H or 5T.
- Using a VUS for prenatal or embryo decisions.
- Confusing newborn screening, sweat testing, and carrier screening.
- Predicting an affected child’s exact severity from genotype alone.
Before a future pregnancy, review older results against current standards. A 23-variant result may still be valid for the variants tested, but expanded testing can reduce residual risk. Store reports permanently and note any later reclassification.
References
- Cystic Fibrosis 2024 (GeneReviews)
- Updated recommendations for CFTR carrier screening: A position statement of the American College of Medical Genetics and Genomics (ACMG) 2023 (Position Statement)
- CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG) 2020 (Technical Standard)
- Standards for the care of people with cystic fibrosis: A timely and accurate diagnosis 2023 (Consensus Standard)
- Cystic fibrosis 2024 (Disease Primer)
- CF Diagnosis Clinical Care Guidelines 2023 (Clinical Guideline)
Disclaimer
This article is educational and does not replace genetic counseling, obstetric care, sweat testing, or evaluation at a cystic fibrosis center. CFTR risk depends on the exact variant pair, phase, test coverage, and current classification. A symptomatic infant, child, or adult should receive diagnostic assessment even when a carrier screen is negative.
